Objectives To prospectively investigate in patients with severe COVID-19-associated
cytokine storm syndrome (CSS) whether an intensive course of glucocorticoids with or …

Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …

Introduction Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients.
Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very …

Background Cytokine storm is a marker of coronavirus disease 2019 (COVID-19) illness
severity and increased mortality. Immunomodulatory treatments have been repurposed to …

Poor outcomes in COVID‐19 correlate with clinical and laboratory features of cytokine storm
syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy …

Objectives To assess the characteristics and risk factors for mortality in patients with severe
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …

Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor,
has been proposed to mitigate the cytokine storm syndrome associated with severe COVID …

Objectives The objective of this study was to estimate the association between tocilizumab
or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 …

Objectives Severe COVID-19 is associated with an imbalanced immune response. We
hypothesized that patients with enhanced inflammation, as demonstrated by increased …

Many patients with severe COVID-19 rapidly progress to critical disease with refractory
hypoxemia requiring invasive mechanical ventilation (IMV). 1 Elevated levels of C reactive …